Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768716 · ClinicalTrials.gov registry record · Phase 4
Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics
A Phase 4 study, sponsored by Tufts University.
- Completed
- Registry status
- Phase 4
- Development phase
- 95
- Enrollment target
NCT00768716 is a Phase 4 study that has completed, run by Tufts University. The registered enrollment target is 95 participants.
The verdict
NCT00768716, a Phase 4 study, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 95 participants
- Enrollment target
Study Summary
Although acetaminophen is the most commonly used nonprescription drug in the USA, little is known regarding the influence of genes and race/ethnicity on acetaminophen disposition. The investigators long-term goal is to understand the causes of differences in acetaminophen disposition between people that are the result of genetic variation and ethnicity and may predispose individuals to a higher risk of acetaminophen hepatotoxicity. The aim of this particular study is to measure the rate of elimination of acetaminophen via the 3 main pathways (glucuronidation, sulfation and oxidation) in self-identified White-Americans (n=100) and African-Americans (n=100). These rates will then be correlated with selected genetic polymorphisms in genes encoding enzymes involved in acetaminophen metabolism. Two main hypotheses will be tested: 1. African-Americans eliminate acetaminophen more rapidly by glucuronidation than do White-Americans. 2. Elimination via glucuronidation, sulfation, and oxidation in subjects will be significantly correlated with the presence of polymorphisms in the UGT1A6, SULT1A1, and CYP2E1 genes, respectively.
Interventions
- DRUG Acetaminophen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768716
The ClinicalTrials.gov registry entry for NCT00768716 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acetaminophen is the first listed.
NCT00768716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768716 about?
NCT00768716 is a clinical study titled "Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics". Although acetaminophen is the most commonly used nonprescription drug in the USA, little is known regarding the influence of genes and race/ethnicity on acetaminophen disposition. The investigators long-term goal is to understand the causes of differences in acetaminophen disposition between people ...
What is the current status of trial NCT00768716?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2008-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00768716?
The interventions under investigation include: Acetaminophen (DRUG).
Who is sponsoring clinical trial NCT00768716?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.